CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) has provided an announcement.
CARsgen Therapeutics Holdings Limited has announced a strategic partnership with Zhuhai Hengqin SB Xinchuang Equity Investment Management Enterprise to accelerate the development of allogeneic CAR-T cell products in mainland China. Through this agreement, CARsgen’s subsidiary, UCARsgen Biotech Limited, will receive a capital infusion of RMB80 million, diluting CARsgen’s stake to 92%. This move is expected to enhance CARsgen’s market positioning in the CAR-T cell therapy space, particularly in China, by securing exclusive rights for the research, development, and commercialization of specific CAR-T products targeting hematologic malignancies.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Limited is a biopharmaceutical company operating in China and the U.S., specializing in innovative CAR T-cell therapies for treating hematologic malignancies and solid tumors. The company has developed a comprehensive research and development platform for CAR T-cell therapies, focusing on improving safety, efficacy, and reducing treatment costs, with a mission to become a global leader in providing differentiated cell therapies for cancer patients worldwide.
YTD Price Performance: 50.27%
Average Trading Volume: 9,778,337
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$7.92B
Learn more about 2171 stock on TipRanks’ Stock Analysis page.